Scratching is an important factor exacerbating skin lesions through the so-called itchscratch cycle in atopic dermatitis (AD). In mice, interleukin (IL)-31 and its receptor IL-31 receptor A (IL-31RA) are known to play a critical role in pruritus and the pathogenesis of AD; however, study of their precise roles in primates is hindered by the low sequence homologies between primates and mice and the lack of direct evidence of itch sensation by IL-31 in primates. We showed that administration of cynomolgus IL-31 induces transient scratching behaviour in cynomolgus monkeys and by that were able to establish a monkey model of scratching. We then showed that a single subcutaneous injection of 1 mg/kg nemolizumab, a humanized anti-human IL-31RA monoclonal antibody that also neutralizes cynomolgus IL-31 signalling and shows a good pharmacokinetic profile in cynomolgus monkeys, suppressed the IL-31-induced scratching for about 2 months. These results suggest that the IL-31 axis and IL-31RA axis play as critical a role in the induction of scratching in primates as in mice and that the blockade of IL-31 signalling by an anti-human IL-31RA antibody is a promising therapeutic approach for treatment of AD. Nemolizumab is currently under investigation in clinical trials.
itch-scratch cycle) and exacerbates skin lesions in AD. [2, 3] Breaking this vicious cycle is considered an effective therapeutic strategy for improving the aggravation of skin lesions and the quality of life in patients with AD.
Interleukin (IL)-31 is a cytokine produced mainly by T h 2 cells [4, 5] and it signals via the IL-31 receptor A (IL-31RA) and oncostatin M receptor (OSMR) β heterodimer. [6, 7] IL-31 receptors are expressed in macrophages, dendritic cells, keratinocytes and neurons. [5, [8] [9] [10] [11] [12] In humans, IL-31 induces pro-inflammatory effects in activated macrophages via signal transducer and activator of transcription (STAT) 1 and STAT5 phosphorylation and induces the production of pro-inflammatory cytokines in monocyte-derived dendritic cells [9, 10] as well as in interferon (IFN)-γ-stimulated keratinocytes. [4, 8, 11] It was recently demonstrated that IL-31 signals through its receptors in sensory neurons in both mice and humans. [5] The expression pattern suggests that IL-31 has pro-inflammatory and sensory functions.
Research on the role of IL-31 in pruritus and AD in mice is well advanced. IL-31 transgenic mice demonstrate continuous scratching behaviour and AD-like skin. Intravenous or subcutaneous administration of mouse IL-31 into normal mice also induces severe pruritus. [4, 13] Furthermore, IL-31RA-deficient mice do not develop pruritus and dermatitis in response to mouse IL-31, [4] and anti-mouse IL-31 antibody ameliorates scratching behaviour in NC/Nga mice with AD. [14] Together, these results indicate the role of the IL-31 axis in pruritus and dermatitis in the pathogenesis of AD in mice. However, because IL-31 and IL-31RA sequences have low homology between rodents and primates-the amino acid identity between humans and mice is 31% for IL-31 and 61% for IL-31RA [4] -it is difficult to extrapolate these rodent results directly to humans. A more exact investigation would require data from experiments in primates, for example in cynomolgus monkeys, which have sequence homology for IL-31 and IL-31RA with humans of 93% and 94%, respectively (Tables S1 and S2 ).
Research has also investigated the nature of IL-31 in humans.
Expression of IL-31 is known to be upregulated in skin taken from patients with AD, [15] [16] [17] and recently Hawro et al. [18] reported that an IL-31 challenge administered by skin prick test evoked a late itch response in healthy volunteers and in patients with AD, from which they concluded that IL-31 exerts its pruritic effect indirectly on cutaneous nerves. However, these results are not conclusive regarding the role of IL-31 in humans because the study was limited to local administration, whereas IL-31RA is expressed in both human skin and dorsal root ganglions (DRG). [12] Furthermore, even though Nemoto et al. [19] have recently reported the antipruritic effect of the anti-hIL-31RA monoclonal antibody nemolizumab (International Nonproprietary Name of CIM331) in AD patients, it still remains unclear whether the antipruritic effect of nemolizumab results from direct inhibition of pruritus or from amelioration of dermatitis, because IL-31 has been shown to have pro-inflammatory actions. Hence, to elucidate the precise roles of the IL-31 axis, it is indispensable to employ whole body experiments in primates without dermatitis.
Taking advantage of the profile of nemolizumab, which has crossreactivity to cyIL-31RA and can inhibit cyIL-31 signalling, we report our investigation of the roles of the IL-31 axis in primates to elucidate the systemic actions of IL-31 and distinguish the antipruritic effects from antidermatitis effects in a newly established IL-31-induced monkey model of scratching.
| MATERIALS AND METHODS

| Animals
Cynomolgus monkey studies were performed in accordance with The company is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International, a nonprofit organization that promotes the humane treatment of animals in science (http://www.aaalac.org/). We used 3-to 5-year-old male monkeys to avoid the effect in a long-term experiment of unrelated bleeding due to menstruation in female monkeys.
| Test materials
Human and cynomolgus IL-31RA DNA was amplified from each tissue-derived cDNA. Soluble forms of the receptors were subcloned into the expression vector to attach the FLAG tag to the C-terminus of the proteins, and each of these proteins was expressed in Chinese hamster ovary (CHO) cells. Human and cynomolgus IL-31RA was purified from the cell supernatant by column chromatography with ANTI-FLAG M2 Agarose Affinity Gel (Sigma-Aldrich, St. Louis, MO, USA)
and HiLoad 26/60 Superdex 200 pg (GE Healthcare, Tokyo, Japan).
Based on its ability to neutralize IL-31 signalling, we selected a lead antibody, NS22, from among mouse anti-human IL-31RA (hIL-31RA) antibodies generated by mice immunized with hIL-31RA and cynomolgus IL-31RA (cyIL-31RA The next day, the cells were cultured in FBS-free medium overnight.
Next, the cells were cultured in FBS-free medium containing human IFN-γ (Peprotech, Rocky Hill, NJ, USA), hIL-31 and nemolizumab for 3 days. The amounts of IL-6, matrix metalloproteinase (MMP)-1 and MMP-3 in the culture supernatant were each determined by enzymelinked immunosorbent assay (ELISA). When the measured value was lower than the detection limit, the detection limit was used as the measured value.
| Establishment of a cynomolgus monkey model of IL-31-induced scratching
CyIL-31 was administered intravenously and the behaviour of monkeys was video-recorded over the next several hours. Scratching behaviour was counted visually in a blinded manner.
| Single-dose PK study in cynomolgus monkeys
Three monkeys in each of six groups were given a single intravenous or subcutaneous injection of 0.04, 0.2 or 1.0 mg/kg nemolizumab (Day 0). Blood was collected at baseline and through to Day 28.
Plasma nemolizumab concentration was determined by solid-phase ELISA using hIL-31RA. Pharmacokinetics (PK) analysis was performed using the WinNonlin Professional Edition computer software, version 5.2.1 (Pharsight Corp., Mountain View, CA, USA).
| Effect of intravenous administration of nemolizumab on IL-31-induced scratching
As described in Supplementary Methods, nemolizumab or vehicle was intravenously administered. The next day, scratching behaviour was induced by intravenous administration of cyIL-31
(1 μg/kg) and counted. Blood was collected just before administration of nemolizumab and cyIL-31, and the plasma concentrations of nemolizumab were measured as above. EC50 was calculated from the scratching counts as a percentage of the baseline cyIL-31-induced scratching count taken before the first nemolizumab administration using XLfit Version 5.1.0.0 (ID Business Solutions
Ltd., Guildford, UK).
| Effect of subcutaneous administration of nemolizumab on IL-31-induced scratching
Twelve monkeys were divided into two groups (vehicle and nemoli- (two-tailed).
| RESULTS
| Binding kinetics of nemolizumab
We generated a humanized anti-hIL-31RA monoclonal antibody, nemolizumab, through optimization of a mouse antibody. Kinetics analysis of nemolizumab binding to human and cynomolgus IL-31RA
showed that nemolizumab bound both receptors with similar values for the dissociation constant (Table S3) .
| Inhibitory effects of nemolizumab on IL-31-dependent proliferation of Ba/F3 cells overexpressing IL-31RA and OSMR β
The Nemolizumab did not inhibit signalling of other gp130 family cytokines (IL-6 and OSM) and showed no antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity (Fig. S1 ).
| Suppression of IL-31 signalling by nemolizumab in human cell lines
Then, we addressed the efficacy of nemolizumab against a native IL-31 signalling system using A549, a human epithelial carcinoma cell line that expresses both IL-31RA and OSMR β. In A549 cells, hIL-31 induced STAT3 phosphorylation, as has been reported. [20] We found that nemolizumab blocked the IL-31 signal ( Figure 1C ).
In an attempt to elucidate the function of IL-31 in skin diseases,
we explored responses to IL-31 stimulation in a human epidermal keratinocyte cell line, HaCaT, which responds to IL-31 at a similar concentration range to the IL-31-induced STAT3 phosphorylation in the normal human epidermal keratinocytes (data not shown).
We found that when IL-31RA expression was enhanced with IFN-γ, IL-31 induced the production of IL-6, MMP-1 and MMP-3. Nemolizumab inhibited all of those IL-31-induced responses ( Figure 1D-F) . These results indicate that nemolizumab suppresses native IL-31 signalling.
| Establishment of a monkey model of IL-31-induced scratching
Next, we investigated whether IL-31 would induce scratching in healthy cynomolgus monkeys by intravenously administering cyIL-31 to monkeys and counting the number of times they scratched.
Scratching behaviour was not observed after a single IL-31 injection of 0.1 μg/kg; however, monkeys started scratching shortly after the injection of 0.5 μg/kg or more (Figure 2A ). The scratch response reached a peak 1-2 hours after administration and then gradually decreased ( Figure 2B ). The number of times a monkey scratched correlated well with the dose of IL-31 in that monkey;
however, the correlation to plasma cyIL-31 concentration could not be evaluated, because the plasma cyIL-31 concentration could not be measured accurately at the low dose levels that induced scratching behaviour in monkeys. Although the response differed among monkeys, the scratch response was constantly observed in all monkeys treated with 1 μg/kg of cyIL-31. Hence, we used an injection of 1 μg/kg cyIL-31 for the monkey model of IL-31-induced scratching.
| Blockade of IL-31-induced scratching by nemolizumab in cynomolgus monkeys
Then, to investigate whether IL-31RA mediates the IL-31-induced scratching response, we examined the inhibitory effect of nemolizumab. We first examined the plasma nemolizumab concentrations after a single intravenous or subcutaneous administration and we found that this antibody has a long-lasting PK profile and good bioavailability from a subcutaneous injection (Table 1 and Fig. S2 ).
We then administered nemolizumab intravenously in a stepwise manner from 3 to 100 μg/kg to increase the plasma nemolizumab concentration ( Figure 3A) . The IL-31-induced scratching was blocked after doses of 40 μg/kg ( Figure 3B ) when plasma nemolizumab concentration was 670 ng/mL (Table S4) were 11 700, 10 800, 3960 and 1240 ng/mL, respectively (Table S5) .
Although in one monkey on Day 56 (Table S6) 
| DISCUSSION
This study investigated the biological function of the IL-31 axis in primates and found that upon intravenous administration of cyIL-31 to cynomolgus monkeys intense scratching was observed.
Furthermore, the scratching behaviour induced by IL-31 was completely inhibited by an anti-IL-31RA antibody, nemolizumab.
Therefore, we conclude that IL-31-induced scratching is mediated by IL-31RA in monkeys in vivo, indicating the biological role of the IL-31 axis in primates. Moreover, the significant suppression of IL-31-induced scratching that was obtained with a single subcutaneous administration of nemolizumab lasted for up to 2 months, which suggests the therapeutic potential of this antibody for AD patients, especially those with pruritus.
In mice, IL-31 transgenic mice and normal mice subcutaneously infused with mouse IL-31 both develop severe pruritus with scratching, and in IL-31RA-deficient mice, alopecia and pruritus do not develop. [4, 13] In dogs, intradermal, subcutaneous or intravenous administration of canine IL-31 increases pruritic behaviour two-to 10-fold from baseline. [21] We demonstrated that intravenously administered cyIL-31 had a scratch-inducing effect like that of systemic murine and canine IL-31, indicating that the function of IL-31 appears to be conserved among species in spite of their low sequence homologies. In fact, the sequence homology of mouse and canine IL-31 with respect to cynomolgus IL-31 is 29% and 55%, respectively (Table S1 ).
In the study by Hawro et al. [18] mentioned earlier, the IL-31 challenge in humans evoked a late itch response with less intensity than that evoked by histamine, but in our study in monkeys the systemic administration of cyIL-31 induced acute scratching behaviour. Species is a clear reason for the difference between the two sets of results, but another major difference between the two studies is the method of administration; that is, the distribution of IL-31 would be limited when it is administered via a skin prick, which suggests that the late itch response seen by Hawro et al. may be a typical local response to IL-31. Interestingly, Lewis et al. [22] recently reported that cyIL-31 administration elicited an immediate scratching response not only by intravenous and subcutaneous but also by intradermal injection. The late itch response may also be closely related to a cellular mechanism of IL-31 action, which we discuss below. [19] is the first evidence indicating the involvement of IL-31 not just in the scratching behaviour but in the itch sensation. However, the paper only evalu- The cellular basis for the scratch-inducing action of IL-31 is yet unclear, but recently Cevikbas et al. [5] reported that IL-31 directly stimulates sensory neurons in mice and the expression of IL-31 and IL-31RA in human immune cells and DRG neuron, respectively, and concluded that IL-31RA is a critical neuroimmune link between T h 2 cells and the sensory nerves, a link that results in T-cell-mediated itching. We used immunohistochemical staining to investigate the localization of IL-31RA in the skin of cynomolgus monkeys. As previously shown in humans and mice, IL-31RA was expressed in the nerve fibres of the skin and DRG in monkeys (Fig. S4 ). These data suggest that cyIL-31 may directly activate itching-related nerve fibres, leading to sensations of itching that then evoke scratching. On the other hand, an indirect pruritic effect of IL-31 through keratinocytes is also proposed by Hawro et al., [18] mainly because of the delayed induction of itching after exposure to IL-31 via skin prick testing. In our study, IL-31 upregulated IL-6, MMP-1 and MMP-3 in HaCaT cells, and these results support the suggestion by Hawro et al. [18] In addition, Kato et al. [12] reported that IL-31RA is expressed not only in nerve fibres but also in keratinocytes in the dermis from AD patients. Thus, further studies clarifying the mechanisms underlying the pruritogenic action of IL-31 in vivo are necessary.
Nemoto et al.'s recent result that blockade of the IL-31 axis with nemolizumab decreases pruritus in AD patients
Recent studies have suggested that IL-31 signalling might play a critical role in the pathogenesis of AD and its accompanying pruritus.
For example, it has been found that skin-homing CLA + T cells from AD patients produce higher levels of IL-31 than do cells from subjects without AD, [15] and serum levels of IL-31 correlate with disease severity in AD patients. [23] These findings and the finding by Nemoto et al., [19] however, did not constitute direct evidence that IL-31 induces severe pruritus through IL-31RA in primates. By making use of both IL-31 and an anti-IL-31RA antibody, our study provides the first evidence that the IL-31 axis in primates mediates a pruritogenic action of IL-31.
T A B L E 1 PK parameters of nemolizumab (CIM331) after a single intravenous or subcutaneous administration in cynomolgus monkeys The mean of two animals is shown because one animal in which ADAs were detected was excluded. Accumulating lines of evidence support the importance of breaking the itch-scratch cycle in the treatment of AD. Although this study did not address the potential of this antibody against dermatitis, we nevertheless believe that nemolizumab has the potential to be effective against dermatitis not only by breaking the itch-scratch cycle but also by its anti-inflammatory potential, because IL-31 induces pro-inflammatory effects in activated macrophages and monocytederived dendritic cells [9, 10] and because our results and the results of others [4, 8, 11] indicate the pro-inflammatory action of IL-31 on 
